In low-grade p53 wild-type bladder cancer, FKA increases the expression of cell cycle inhibitors p21 and p27, leading to G1 arrest in cell cycle progression, whereas FKA decreases the expression of Myt1 and Wee1 and increases the expression of cyclin B1, resulting in a G2-M arrest in p53 mutant-type, muscle-invasive, or metastatic bladder cancer cells [10]. This evidence concerns the gene WEE1 and urinary bladder carcinoma.